263 related articles for article (PubMed ID: 16361629)
1. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.
Hennessy BT; Hortobagyi GN; Rouzier R; Kuerer H; Sneige N; Buzdar AU; Kau SW; Fornage B; Sahin A; Broglio K; Singletary SE; Valero V
J Clin Oncol; 2005 Dec; 23(36):9304-11. PubMed ID: 16361629
[TBL] [Abstract][Full Text] [Related]
2. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy.
Hennessy BT; Gonzalez-Angulo AM; Hortobagyi GN; Cristofanilli M; Kau SW; Broglio K; Fornage B; Singletary SE; Sahin A; Buzdar AU; Valero V
Cancer; 2006 Mar; 106(5):1000-6. PubMed ID: 16444747
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases.
Sakakibara M; Nagashima T; Kadowaki M; Onai Y; Fujimori T; Yokomizo J; Suzuki H; Fushimi K; Nakatani Y; Miyazaki M
Ann Surg Oncol; 2009 Sep; 16(9):2470-8. PubMed ID: 19588201
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
5. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome.
Mazouni C; Peintinger F; Wan-Kau S; Andre F; Gonzalez-Angulo AM; Symmans WF; Meric-Bernstam F; Valero V; Hortobagyi GN; Pusztai L
J Clin Oncol; 2007 Jul; 25(19):2650-5. PubMed ID: 17602071
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes in stage IIIB breast cancer patients who achieved less than a pathological complete response (Ionta MT; Atzori F; Deidda MC; Pusceddu V; Palmeri S; Frau B; Murgia M; Barca M; Minerba L; Massidda B
Oncologist; 2009 Nov; 14(11):1051-60. PubMed ID: 19897535
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of initial clinical disease stage after achieving pathological complete response.
Dawood S; Broglio K; Kau SW; Islam R; Symmans WF; Buchholz TA; McGuire SE; Meric-Bernstam F; Cristofanilli M; Hortobágyi GN; Gonzalez-Angulo AM
Oncologist; 2008 Jan; 13(1):6-15. PubMed ID: 18245008
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Cho N; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
Breast Cancer Res Treat; 2009 Jul; 116(1):153-60. PubMed ID: 18787948
[TBL] [Abstract][Full Text] [Related]
10. Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.
Gonzalez-Angulo AM; McGuire SE; Buchholz TA; Tucker SL; Kuerer HM; Rouzier R; Kau SW; Huang EH; Morandi P; Ocana A; Cristofanilli M; Valero V; Buzdar AU; Hortobagyi GN
J Clin Oncol; 2005 Oct; 23(28):7098-104. PubMed ID: 16192593
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
Shen J; Gilcrease MZ; Babiera GV; Ross MI; Meric-Bernstam F; Feig BW; Kuerer HM; Francis A; Ames FC; Hunt KK
Cancer; 2007 Apr; 109(7):1255-63. PubMed ID: 17330229
[TBL] [Abstract][Full Text] [Related]
13. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer.
Cox CE; Cox JM; White LB; Stowell NG; Clark JD; Allred N; Meyers M; Dupont E; Furman B; Minton S
Ann Surg Oncol; 2006 Apr; 13(4):483-90. PubMed ID: 16523361
[TBL] [Abstract][Full Text] [Related]
14. Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features.
Montagna E; Bagnardi V; Rotmensz N; Viale G; Pruneri G; Veronesi P; Cancello G; Balduzzi A; Dellapasqua S; Cardillo A; Luini A; Zurrida S; Gentilini O; Mastropasqua MG; Bottiglieri L; Iorfida M; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2010 Dec; 124(3):689-99. PubMed ID: 20625816
[TBL] [Abstract][Full Text] [Related]
15. Management and outcomes of isolated axillary node recurrence in breast cancer.
Konkin DE; Tyldesley S; Kennecke H; Speers CH; Olivotto IA; Davis N
Arch Surg; 2006 Sep; 141(9):867-72; discussion 872-4. PubMed ID: 16983030
[TBL] [Abstract][Full Text] [Related]
16. Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy.
Er O; Frye DK; Kau SW; Broglio K; Valero V; Hortobagyi GN; Arun B
Cancer J; 2008; 14(1):62-8. PubMed ID: 18303485
[TBL] [Abstract][Full Text] [Related]
17. Incidence and prognostic significance of complete axillary downstaging after primary chemotherapy in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes.
Rouzier R; Extra JM; Klijanienko J; Falcou MC; Asselain B; Vincent-Salomon A; Vielh P; Bourstyn E
J Clin Oncol; 2002 Mar; 20(5):1304-10. PubMed ID: 11870173
[TBL] [Abstract][Full Text] [Related]
18. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
Symmans WF; Peintinger F; Hatzis C; Rajan R; Kuerer H; Valero V; Assad L; Poniecka A; Hennessy B; Green M; Buzdar AU; Singletary SE; Hortobagyi GN; Pusztai L
J Clin Oncol; 2007 Oct; 25(28):4414-22. PubMed ID: 17785706
[TBL] [Abstract][Full Text] [Related]
19. Patterns of local and distant disease relapse in patients with breast cancer treated with primary chemotherapy: do patients with a complete pathological response differ from those with residual tumour in the breast?
Chaturvedi S; McLaren C; Schofield AC; Ogston KN; Sarkar TK; Hutcheon AW; Miller ID; Heys SD
Breast Cancer Res Treat; 2005 Sep; 93(2):151-8. PubMed ID: 16187235
[TBL] [Abstract][Full Text] [Related]
20. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
